1st Quarter - Report

FERRING PHARMACEUTICALS, INC. for FERRING PHARMACEUTICALS, INC.

Firm
Client
Income
—
Expenses
$13,500
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

S. 2960, H. 5965, "Access to Infertility Treatment Act." Legislation to require that health plans offered on the group and individual markets, in addition to the FEHB Program, TRICARE, and the VA provide coverage for in vitro fertility (IVF) treatments and fertility preservation treatments for patients who undergo medically necessary procedures that may cause infertility, such as chemotherapy. H.R. 2097, "The Drug Pricing Transparency Act." Pertaining to manufacturer reporting to CMS of the average sales price (ASP) of products reimbursed by Medicare Part B drugs, specifically including products approved by the FDA as medical devices.

Foreign entity interest: Ferring International S.A. (Ferring Global) supports the policy issues listed above.

LobbyistCovered position, as disclosed
LILLIAN VERNE GERMAN Senior Counsel, House Judiciary Committee; Chief of Staff, Rep. E.B. Johnson, Rep. Alcee Hastings, Rep. Sheila Jackson Lee, Rep. Barbara Lee

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Veterans Affairs, Dept of (VA); Centers For Medicare and Medicaid Services (CMS); SENATE

Bills named: S. 2960 (116th), H.R. 2097 (116th)

Support LegiList

This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.

Processed by Stripe in a separate window. LegiList never sees card details. Other amounts

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.